Ofatumumab Market

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
Ofatumumab Market contains market size and forecasts of Ofatumumab in global, including the following market information:
Global Ofatumumab Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ofatumumab Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Ofatumumab companies in 2021 (%)
The global Ofatumumab market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Patent Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ofatumumab include BOC Sciences, GlaxoSmithKline(GSK), Lonza Group, Novartis International, TargetMol Chemicals, Hubei Kele Fine Chemical, Jiangxi Ruiweier Biotechnology, Nantong Feiyu Biological Technology and Shanghai Biochempartner, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Ofatumumab manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ofatumumab Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Ofatumumab Market Segment Percentages, by Type, 2021 (%)
Patent
Generic
Global Ofatumumab Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Ofatumumab Market Segment Percentages, by Application, 2021 (%)
Chemical
Pharmaceutical
Global Ofatumumab Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Ofatumumab Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ofatumumab revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ofatumumab revenues share in global market, 2021 (%)
Key companies Ofatumumab sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Ofatumumab sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
BOC Sciences
GlaxoSmithKline(GSK)
Lonza Group
Novartis International
TargetMol Chemicals
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Nantong Feiyu Biological Technology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Yifei Biotechnology
Tianmen Hengchang Chemical
Wuhan Topule Biopharmaceutical
Wuhan Wogeda Biotechnology
Wuhan Yingnuo Pharmaceutical Technology